Memorial Sloan Kettering Cancer Center, New York, NY
Andrea Cercek , Melissa Amy Lumish , Jenna Cohen Sinopoli , Jill A. Weiss , Jinru Shia , Zsofia Kinga Stadler , Rona Yaeger , Jesse Joshua Smith , Leonard B. Saltz , Imane H. El Dika , Christopher H. Crane , Paul Bernard Romesser , Kirshna Iyer , Philip Paty , Julio Garcia-Aguilar , Mithat Gonen , Marc J Gollub , Martin R. Weiser , Kurt A. Schalper , Luis A. Diaz Jr.
Background: Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is mismatch repair deficient. Since mismatch repair deficient colorectal cancer is responsive to PD-1 blockade in the metastatic setting, we hypothesized that locally advanced mismatch repair deficient rectal cancer is sensitive to checkpoint blockade and may alter the requirements for chemoradiotherapy and surgery. Methods: We conducted a prospective phase II study in which single agent dostarlimab, an anti PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair deficient stage II and III rectal adenocarcinoma, to be followed by standard chemoradiation and surgery. Patients who achieved a clinical complete response were eligible for omission of chemoradiation and surgery. Results: Twelve patients initiated treatment and have at least 6 months of follow up. All 12 (100%, 95% CI:74%-100%) achieved a clinical complete response with no evidence of tumor on MRI, FDG-PET, endoscopic visualization, digital rectal exam, or biopsy, which satisfied the study’s co-primary endpoint. To date, no patients have required chemoradiation or surgery, and no cases of progression or recurrence have been noted during follow up (range 6-25 months). No serious adverse events > grade 3 were observed. Conclusions: Mismatch repair deficient locally advanced rectal cancer is exceptionally sensitive to single agent PD-1 blockade. Longer follow up is needed to assess response duration. Clinical trial information: NCT04165772.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Melissa Amy Lumish
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Melissa Amy Lumish
2024 ASCO Annual Meeting
First Author: Andrea Cercek
2023 ASCO Annual Meeting
First Author: Andrea Cercek